Movement Alert|CRISPR Therapeutics AG Falls 5.2% in Regular Trading, Buy-Rating Reiteration Fails to Lift Shares

Market Focus
11/17

On November 17, CRISPR Therapeutics AG fell 5.2% in Regular Trading, trading at $40.045 per share, with turnover of $47.3887 million.

The latest identifiable catalyst was an event-driven update: an analyst reiterated a Buy rating and set an $80 price target, but the move did not provide visible support for the shares, with trading still reflecting caution around the pace of commercialization and early-pipeline execution.

Recent company updates show mixed fundamentals and pipeline momentum. The company reported quarterly EPS of $(1.15), missing the $(0.98) consensus estimate, while revenue of $12.669 million beat the $10.495 million estimate. Separately, Casgevy use was described as continuing to grow, and earlier Phase 1b data for CTX310 showed average ANGPTL3 reduction of 65% and triglyceride reduction of 63%, alongside early positive autoimmune data for zugo-cel.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10